The Pan-Immune-Inflammation Value predicts the survival of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer treated with first-line ALK inhibitor

BACKGROUND: Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have significantly improved the clinical outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC). However, reliable biomarkers to predict the prognostic role of this treatment are lacking. The Pan-Immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xinru, Hong, Xiangchan, Chen, Gang, Xue, Jinhui, Huang, Jie, Wang, Fan, Ali, Wael Ab dullah Sultan, Li, Jing, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749135/
https://www.ncbi.nlm.nih.gov/pubmed/34999541
http://dx.doi.org/10.1016/j.tranon.2021.101338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749135/
https://www.ncbi.nlm.nih.gov/pubmed/34999541
http://dx.doi.org/10.1016/j.tranon.2021.101338

Ejemplares similares